Invitae Announces Exercise in Full of Underwriters' Option to Purchase Additional Shares of Common Stock and Closing of Underwritten Public Offering
Invitae Corporation (NYSE: NVTA) completed an underwritten public offering of 8,932,038 shares of common stock, raising approximately $460 million at a price of $51.50 per share. This includes shares sold following the full exercise of underwriters' options. The offering was managed by J.P. Morgan, Morgan Stanley, Cowen, and SVB Leerink. The registration statement for this offering has been effective since March 4, 2019. Invitae aims to integrate comprehensive genetic information into standard medical practice, enhancing healthcare accessibility.
- Successfully raised approximately $460 million in gross proceeds.
- Funds intended to enhance Invitae's position in the genetics market.
- Dilution risk for existing shareholders due to the issuance of additional shares.
SAN FRANCISCO, Jan. 26, 2021 /PRNewswire/ -- Invitae Corporation (NYSE: NVTA) today announced the closing of its underwritten public offering of 8,932,038 shares of its common stock, including 1,165,048 shares sold pursuant to the exercise in full of the underwriters' option to purchase additional shares, at the public offering price of
J.P. Morgan Securities LLC, Morgan Stanley, Cowen and Company, LLC and SVB Leerink LLC acted as the book-running managers for the offering. William Blair & Company, L.L.C. acted as co-manager for the offering.
An automatic shelf registration statement relating to the shares was filed with the Securities and Exchange Commission and became effective on March 4, 2019. A copy of the final prospectus supplement and accompanying prospectus relating to the offering may be obtained from J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, by telephone at (866) 803-9204, or by email at prospectus-eq_fi@jpmchase.com; from Morgan Stanley & Co. LLC, 180 Varick Street, 2nd Floor, New York, NY, 10014, Attention: Prospectus Department; from Cowen and Company, LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, Attn: Prospectus Department, by email at PostSaleManualRequests@broadridge.com, or by telephone at (833) 297-2926; or from SVB Leerink LLC, One Federal Street, 37th Floor, Boston, MA 02110, Attention: Syndicate Department, by telephone at (800) 808-7535, ext. 6132, or by email at syndicate@svbleerink.com.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
About Invitae Corporation
Invitae Corporation (NYSE: NVTA) is a leading medical genetics company whose mission is to bring comprehensive genetic information into mainstream medicine to improve healthcare for billions of people. Invitae's goal is to aggregate the world's genetic tests into a single service with higher quality, faster turnaround time, and lower prices.
Contact:
Laura D'Angelo
ir@invitae.com
(628) 213-3369
View original content to download multimedia:http://www.prnewswire.com/news-releases/invitae-announces-exercise-in-full-of-underwriters-option-to-purchase-additional-shares-of-common-stock-and-closing-of-underwritten-public-offering-301215534.html
SOURCE Invitae Corporation
FAQ
What was the purpose of Invitae's public offering on January 26, 2021?
How many shares did Invitae sell in its public offering?
What were the gross proceeds from Invitae's stock offering?
What was the offering price per share for Invitae's stock?
